Nguyen Mindie H, Keeffe Emmet B
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Clin Liver Dis. 2005 Aug;9(3):411-26, vi. doi: 10.1016/j.cld.2005.05.010.
Infection with hepatitis C virus (HCV) genotypes 1, 2, or 3 is widely distributed throughout the world and has been the focus of the majority of studies on the epidemiology and treatment of chronic hepatitis C. Infection with HCV genotypes 4 through 9 is prevalent in some geographic areas where the disease burden of chronic hepatitis C approaches endemic levels (eg, HCV genotype 4 in Egypt where there is an HCV infection prevalence of approximately 18%). This article reviews the existing literature, which suggests that chronic hepatitis C with genotypes 4 through 9 may exhibit epidemiologic, clinical, and treatment outcome differences from infection with genotypes 1, 2, or 3.
丙型肝炎病毒(HCV)1、2或3型感染在全球广泛分布,并且一直是大多数慢性丙型肝炎流行病学和治疗研究的重点。HCV 4至9型感染在一些慢性丙型肝炎疾病负担接近地方流行水平的地理区域较为普遍(例如,埃及的HCV 4型,该国HCV感染率约为18%)。本文回顾了现有文献,这些文献表明,HCV 4至9型慢性丙型肝炎在流行病学、临床和治疗结果方面可能与1、2或3型感染有所不同。